**Core Concept**
Aspirin's antiplatelet action is a result of its irreversible inhibition of cyclooxygenase (COX) enzymes, specifically COX-1, which are crucial for the production of thromboxane A2 (TXA2) in platelets.

**Why the Correct Answer is Right**
Aspirin's mechanism of action involves the irreversible acetylation of a serine residue in the active site of COX-1. This modification prevents the enzyme from converting arachidonic acid into prostaglandin H2 (PGH2), which is then converted to TXA2. TXA2 is a potent vasoconstrictor and stimulates platelet aggregation. By inhibiting TXA2 production, aspirin reduces platelet aggregation and thus exerts its antiplatelet effect. This mechanism is specific to platelets, as COX-1 is highly expressed in these cells, whereas COX-2 is primarily found in other tissues.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is often incorrect as it does not specify the correct mechanism of action.
**Option B:** This option may be incorrect as it does not accurately describe the enzyme involved in aspirin's antiplatelet action.
**Option C:** This option may be incorrect as it does not accurately describe the final product that aspirin inhibits the production of.

**Clinical Pearl / High-Yield Fact**
Aspirin's antiplatelet effect is not limited to its inhibition of COX-1; it also has anti-inflammatory properties through its inhibition of COX-2. However, the antiplatelet effect is more relevant to its clinical use in preventing thrombotic events.

**Correct Answer: A. Irreversible inhibition of COX-1 enzymes.**